Adalimumab Therapy in a Patient with Psoriasis, Down Syndrome, and Concomitant Hepatitis B Virus Infection

Abdulaziz Madani,1 Qais Almuhaideb2 1Department of Dermatology, College of Medicine, King Saud University, Riyadh, Saudi Arabia; 2College of Medicine, King Saud University, Riyadh, Saudi ArabiaCorrespondence: Abdulaziz MadaniKing Saud University, Riyadh, 11451, Saudi ArabiaTel +966 1-80 66481Fax +96...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Madani A, Almuhaideb Q
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2021
Materias:	adalimumab biologics trisomy 21 hbv Medicine (General) R5-920
Acceso en línea:	https://doaj.org/article/b202cf0fa73d4d00a4effa0fecd8b8b2
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:b202cf0fa73d4d00a4effa0fecd8b8b2
record_format	dspace
spelling	oai:doaj.org-article:b202cf0fa73d4d00a4effa0fecd8b8b22021-12-02T19:02:21ZAdalimumab Therapy in a Patient with Psoriasis, Down Syndrome, and Concomitant Hepatitis B Virus Infection1177-5491https://doaj.org/article/b202cf0fa73d4d00a4effa0fecd8b8b22021-09-01T00:00:00Zhttps://www.dovepress.com/adalimumab-therapy-in-a-patient-with-psoriasis-down-syndrome-and-conco-peer-reviewed-fulltext-article-BTThttps://doaj.org/toc/1177-5491Abdulaziz Madani,1 Qais Almuhaideb2 1Department of Dermatology, College of Medicine, King Saud University, Riyadh, Saudi Arabia; 2College of Medicine, King Saud University, Riyadh, Saudi ArabiaCorrespondence: Abdulaziz MadaniKing Saud University, Riyadh, 11451, Saudi ArabiaTel +966 1-80 66481Fax +966114671992Email Amadani1@ksu.edu.saAbstract: Down syndrome is the most common chromosomal disorder and may present with a combination of dysmorphic features, congenital heart disease, and immunological deficiency. The association between Down syndrome and psoriasis is unclear. The prevalence of psoriasis in patients with Down syndrome ranges from 0.5% to 8%. The safety of biologics in the treatment of Down syndrome-related psoriasis is still debated. Down syndrome results in mild immunological abnormalities; consequently, the risk of infectious complications during immunosuppressive therapy might be higher in this group of patients. We report a case of a 33-year-old male, a case of chronic plaque psoriasis, Down syndrome (DS), asthma, and hepatitis B. The patient was started on Calcipotriene 0.005%-betamethasone 0.064% ointment, which failed to control the patient’s psoriasis; thus, adalimumab was started. His response to adalimumab was significant, where over 70% improvement of the psoriatic lesions was seen.Keywords: adalimumab, biologics, trisomy 21, HBVMadani AAlmuhaideb QDove Medical Pressarticleadalimumabbiologicstrisomy 21hbvMedicine (General)R5-920ENBiologics: Targets & Therapy, Vol Volume 15, Pp 375-378 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	adalimumab biologics trisomy 21 hbv Medicine (General) R5-920
spellingShingle	adalimumab biologics trisomy 21 hbv Medicine (General) R5-920 Madani A Almuhaideb Q Adalimumab Therapy in a Patient with Psoriasis, Down Syndrome, and Concomitant Hepatitis B Virus Infection
description	Abdulaziz Madani,1 Qais Almuhaideb2 1Department of Dermatology, College of Medicine, King Saud University, Riyadh, Saudi Arabia; 2College of Medicine, King Saud University, Riyadh, Saudi ArabiaCorrespondence: Abdulaziz MadaniKing Saud University, Riyadh, 11451, Saudi ArabiaTel +966 1-80 66481Fax +966114671992Email Amadani1@ksu.edu.saAbstract: Down syndrome is the most common chromosomal disorder and may present with a combination of dysmorphic features, congenital heart disease, and immunological deficiency. The association between Down syndrome and psoriasis is unclear. The prevalence of psoriasis in patients with Down syndrome ranges from 0.5% to 8%. The safety of biologics in the treatment of Down syndrome-related psoriasis is still debated. Down syndrome results in mild immunological abnormalities; consequently, the risk of infectious complications during immunosuppressive therapy might be higher in this group of patients. We report a case of a 33-year-old male, a case of chronic plaque psoriasis, Down syndrome (DS), asthma, and hepatitis B. The patient was started on Calcipotriene 0.005%-betamethasone 0.064% ointment, which failed to control the patient’s psoriasis; thus, adalimumab was started. His response to adalimumab was significant, where over 70% improvement of the psoriatic lesions was seen.Keywords: adalimumab, biologics, trisomy 21, HBV
format	article
author	Madani A Almuhaideb Q
author_facet	Madani A Almuhaideb Q
author_sort	Madani A
title	Adalimumab Therapy in a Patient with Psoriasis, Down Syndrome, and Concomitant Hepatitis B Virus Infection
title_short	Adalimumab Therapy in a Patient with Psoriasis, Down Syndrome, and Concomitant Hepatitis B Virus Infection
title_full	Adalimumab Therapy in a Patient with Psoriasis, Down Syndrome, and Concomitant Hepatitis B Virus Infection
title_fullStr	Adalimumab Therapy in a Patient with Psoriasis, Down Syndrome, and Concomitant Hepatitis B Virus Infection
title_full_unstemmed	Adalimumab Therapy in a Patient with Psoriasis, Down Syndrome, and Concomitant Hepatitis B Virus Infection
title_sort	adalimumab therapy in a patient with psoriasis, down syndrome, and concomitant hepatitis b virus infection
publisher	Dove Medical Press
publishDate	2021
url	https://doaj.org/article/b202cf0fa73d4d00a4effa0fecd8b8b2
work_keys_str_mv	AT madania adalimumabtherapyinapatientwithpsoriasisdownsyndromeandconcomitanthepatitisbvirusinfection AT almuhaidebq adalimumabtherapyinapatientwithpsoriasisdownsyndromeandconcomitanthepatitisbvirusinfection
_version_	1718377289216950272

Adalimumab Therapy in a Patient with Psoriasis, Down Syndrome, and Concomitant Hepatitis B Virus Infection

Ejemplares similares